Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Methylergometrine (0.125mg)
Therapeutic Category
ENDOCRINOLOGY and Hormonal range, Gynecology and Fertility
Dosage Form
Injection
Packaging Type
Vial
Packaging
1ml
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Methezen 0.125 Injection contains Methylergometrine (0.125mg), an ergot alkaloid that plays a vital role in controlling postpartum bleeding caused by uterine atony. After childbirth, if the uterus fails to contract properly, excessive bleeding can occur, leading to life-threatening conditions. This injection helps stimulate uterine contractions, which is essential for reducing blood loss and stabilizing the patient’s condition.
Administered by a healthcare professional, Utilair 0.125 Injection is primarily used in obstetrics, specifically in situations where there is a risk of postpartum hemorrhage, a common complication after delivery. Methylergometrine’s action aids in controlling excessive bleeding by promoting the contraction of the uterus, ensuring that it returns to its normal size and reducing the risk of further blood loss.
This injection is typically used in a clinical or hospital setting, ensuring close monitoring of the patient to avoid any adverse reactions. It provides quick and effective control over postpartum hemorrhage, a crucial part of post-delivery care. The dosage and timing of the injection are determined by the healthcare provider based on the patient's condition.
Possible side effects include nausea, vomiting, headache, dizziness, and high blood pressure. Rarely, more severe reactions such as vasoconstriction and seizures may occur.
Utilair 0.125 Injection is indicated for the prevention and management of postpartum hemorrhage due to uterine atony, assisting in the contraction of the uterus after childbirth.
Administer only under the supervision of a healthcare provider. Not suitable for patients with hypertension or cardiovascular disorders without prior consultation.
Store at room temperature, away from moisture and heat. Keep out of reach of children.
Composition : Bromfenac (0.09% w/v) + Moxifloxacin (0.5% w/v)
Composition : Bromfenac (0.9mg) Eye Drops
Composition : Carboxymethylcellulose (3mg/ml) + Glycerin (10mg/ml) + n-acetylcarnosine (10mg/ml)
Composition : Dexamethasone (0.1% w/v) + Tobramycin (0.3% w/v)
Composition : Fluconazole (0.3% w/v)
Composition : Gatifloxacin (0.3% w/v)
Composition : Ketorolac (0.4% w/v) + Olopatadine (0.1% w/v)
Composition : Ketorolac (0.5% w/v)
Composition : Ketorolac (5% w/v) + Moxifloxacin (0.5% w/v)
Composition : Loteprednol etabonate (0.5% w/v)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Methylergometrine 0.125 mg Injection is a uterotonic (oxytocic) medicine used in obstetrics to manage and prevent postpartum hemorrhage (PPH) and to help control uterine bleeding after delivery or abortion. It works by increasing uterine muscle contractions. It is a strong gynecology and obstetric emergency injectable segment product, mainly used in hospitals, maternity homes, and delivery centers under medical supervision.
Medical distributors and wholesalers can benefit from consistent hospital and maternity hospital demand, especially in delivery cases and gynecology emergency protocols. It is an essential obstetric emergency medicine, ensuring reliable institutional procurement and steady turnover in hospital supply chains.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities in gynecology, obstetric emergency, and injectable hospital segments with monopoly rights, quality manufacturing standards, and reliable supply support for distributors and medical agencies.
Wholesalers and institutional suppliers benefit from steady maternity hospital demand, surgical and delivery room usage, and emergency obstetric protocols, making it a stable and essential pharmaceutical category when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in gynecology and obstetric injectable products can contact Cafoli Lifecare to discuss hospital supply requirements, pricing, and PCD pharma franchise opportunities in the maternity and critical-care segment.